Abstract
Background/Aims: This study was conducted to determine the effect of telmisartan on the cardio-ankle vascular index (CAVI), a novel blood pressure (BP)-independent marker for arterial stiffness in hypertensive patients. Methods: One hundred consecutive hypertensive patients were randomly assigned either to a group treated with calcium channel blocker (CCB)-based therapy or a group treated with telmisartan-based therapy. Clinical and biological parameters were then measured before and 12 months after the start of this study. Results: CAVI, the logarithm of urinary albumin excretion, and BP were reduced significantly after telmisartan-based therapy. The decreases in 24-hour diastolic BP and daytime systolic BP associated with telmisartan-based therapy were significantly greater than those associated with CCB-based therapy. Both therapies significantly and similarly decreased the clinical BP, 24-hour systolic BP, daytime diastolic BP and serum levels of low-density lipoprotein cholesterol. No significant differences in the metabolic parameters were observed between the two therapies. Conclusion: Telmisartan-based therapy had beneficial effects on arterial stiffness assessed by CAVI, albuminuria, 24-hour BP and metabolism compared with CCB-based therapy. Since these markers are known to influence the future risk of cardiovascular events, telmisartan could be a useful drug for hypertensive patients.
| Original language | English |
|---|---|
| Pages (from-to) | 304-312 |
| Number of pages | 9 |
| Journal | Kidney and Blood Pressure Research |
| Volume | 33 |
| Issue number | 4 |
| DOIs | |
| Publication status | Published - 2010 Aug |
Fingerprint
Keywords
- Albuminuria
- Arterial stiffness
- Blood pressure
- Cardio-ankle vascular index
- Telmisartan
ASJC Scopus subject areas
- Nephrology
- Cardiology and Cardiovascular Medicine
Cite this
Effects of telmisartan on arterial stiffness assessed by the cardio-ankle vascular index in hypertensive patients. / Kinouchi, Kenichiro; Ichihara, Atsuhiro; Sakoda, Mariyo; Kurauchi-Mito, Asako; Murohashi-Bokuda, Kanako; Itoh, Hiroshi.
In: Kidney and Blood Pressure Research, Vol. 33, No. 4, 08.2010, p. 304-312.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Effects of telmisartan on arterial stiffness assessed by the cardio-ankle vascular index in hypertensive patients
AU - Kinouchi, Kenichiro
AU - Ichihara, Atsuhiro
AU - Sakoda, Mariyo
AU - Kurauchi-Mito, Asako
AU - Murohashi-Bokuda, Kanako
AU - Itoh, Hiroshi
PY - 2010/8
Y1 - 2010/8
N2 - Background/Aims: This study was conducted to determine the effect of telmisartan on the cardio-ankle vascular index (CAVI), a novel blood pressure (BP)-independent marker for arterial stiffness in hypertensive patients. Methods: One hundred consecutive hypertensive patients were randomly assigned either to a group treated with calcium channel blocker (CCB)-based therapy or a group treated with telmisartan-based therapy. Clinical and biological parameters were then measured before and 12 months after the start of this study. Results: CAVI, the logarithm of urinary albumin excretion, and BP were reduced significantly after telmisartan-based therapy. The decreases in 24-hour diastolic BP and daytime systolic BP associated with telmisartan-based therapy were significantly greater than those associated with CCB-based therapy. Both therapies significantly and similarly decreased the clinical BP, 24-hour systolic BP, daytime diastolic BP and serum levels of low-density lipoprotein cholesterol. No significant differences in the metabolic parameters were observed between the two therapies. Conclusion: Telmisartan-based therapy had beneficial effects on arterial stiffness assessed by CAVI, albuminuria, 24-hour BP and metabolism compared with CCB-based therapy. Since these markers are known to influence the future risk of cardiovascular events, telmisartan could be a useful drug for hypertensive patients.
AB - Background/Aims: This study was conducted to determine the effect of telmisartan on the cardio-ankle vascular index (CAVI), a novel blood pressure (BP)-independent marker for arterial stiffness in hypertensive patients. Methods: One hundred consecutive hypertensive patients were randomly assigned either to a group treated with calcium channel blocker (CCB)-based therapy or a group treated with telmisartan-based therapy. Clinical and biological parameters were then measured before and 12 months after the start of this study. Results: CAVI, the logarithm of urinary albumin excretion, and BP were reduced significantly after telmisartan-based therapy. The decreases in 24-hour diastolic BP and daytime systolic BP associated with telmisartan-based therapy were significantly greater than those associated with CCB-based therapy. Both therapies significantly and similarly decreased the clinical BP, 24-hour systolic BP, daytime diastolic BP and serum levels of low-density lipoprotein cholesterol. No significant differences in the metabolic parameters were observed between the two therapies. Conclusion: Telmisartan-based therapy had beneficial effects on arterial stiffness assessed by CAVI, albuminuria, 24-hour BP and metabolism compared with CCB-based therapy. Since these markers are known to influence the future risk of cardiovascular events, telmisartan could be a useful drug for hypertensive patients.
KW - Albuminuria
KW - Arterial stiffness
KW - Blood pressure
KW - Cardio-ankle vascular index
KW - Telmisartan
UR - http://www.scopus.com/inward/record.url?scp=77954878070&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77954878070&partnerID=8YFLogxK
U2 - 10.1159/000316724
DO - 10.1159/000316724
M3 - Article
VL - 33
SP - 304
EP - 312
JO - Kidney and Blood Pressure Research
JF - Kidney and Blood Pressure Research
SN - 1420-4096
IS - 4
ER -